Payment overview · 2025
General Payments
$345.70
11 reported records · 8 companies
Healthcare provider profile · identity verified
John P Odonnell, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · LAKE CITY, FL · NPI 1891795175
Verified facts
What the public records show
CMS Open Payments records show John P Odonnell, PA-C received $345.70 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 58.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $203.23 | 58.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $34.40 | 9.9% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $23.07 | 6.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.50 | 5.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.43 | 5.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.47 | 4.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.12 | 4.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.48 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $345.70 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $203.23 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $178.11 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $178.11 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 92 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
104 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
92 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
92 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
55 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
213 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 694 | 201 |
| Amlodipine Besylate | Amlodipine Besylate | 498 | 151 |
| Gabapentin | Gabapentin | 492 | 120 |
| Lisinopril | Lisinopril | 410 | 126 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 348 | 104 |
| Omeprazole | Omeprazole | 332 | 113 |
| Losartan Potassium | Losartan Potassium | 320 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 79 |
| Diclofenac Sodium | Diclofenac Sodium | 268 | 102 |
| Fluticasone Propionate | Fluticasone Propionate | 239 | 85 |
| Metformin Hcl | Metformin Hcl | 239 | 76 |
| Buspirone Hcl | Buspirone Hcl | 217 | 59 |
| Ozempic | Semaglutide | 213 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 201 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 197 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 52 |
| Montelukast Sodium | Montelukast Sodium | 175 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 153 | 34 |
| Carvedilol | Carvedilol | 149 | 45 |
| Furosemide | Furosemide | 149 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 148 | 50 |
| Bumetanide | Bumetanide | 146 | 42 |
| Trazodone Hcl | Trazodone Hcl | 144 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 137 | 37 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 136 | 49 |
| Paroxetine Hcl | Paroxetine Hcl | 128 | 27 |
| Baclofen | Baclofen | 127 | 53 |
| Simvastatin | Simvastatin | 124 | 38 |
| Eliquis | Apixaban | 123 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 123 | 38 |
| Prednisone | Prednisone | 122 | 90 |
| Meloxicam | Meloxicam | 119 | 34 |
| Dicyclomine Hcl | Dicyclomine Hcl | 117 | 34 |
| Ondansetron Hcl | Ondansetron Hcl | 115 | 42 |
| Amitriptyline Hcl | Amitriptyline Hcl | 114 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 32 |
| Ibuprofen | Ibuprofen | 114 | 31 |
| Ibandronate Sodium | Ibandronate Sodium | 113 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 113 | 36 |
| Cephalexin | Cephalexin | 111 | 88 |
| Potassium Chloride | Potassium Chloride | 105 | 32 |
| Famotidine | Famotidine | 104 | 31 |
| Linzess | Linaclotide | 104 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 104 | 55 |
| Meclizine Hcl | Meclizine Hcl | 99 | 36 |
| Allopurinol | Allopurinol | 98 | 22 |
| Topiramate | Topiramate | 98 | 28 |
| Farxiga | Dapagliflozin Propanediol | 92 | 21 |
| Naproxen | Naproxen | 92 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 92 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 84 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 30 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 76 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 75 | 24 |
| Primidone | Primidone | 75 | 18 |
| Jardiance | Empagliflozin | 74 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 18 |
| Sucralfate | Sucralfate | 74 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 18 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 70 | 26 |
| Clonidine Hcl | Clonidine Hcl | 69 | 20 |
| Repatha Sureclick | Evolocumab | 69 | 12 |
| Ezetimibe | Ezetimibe | 68 | 20 |
| Ketoconazole | Ketoconazole | 65 | 28 |
| Glipizide | Glipizide | 63 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 19 |
| Sertraline Hcl | Sertraline Hcl | 60 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 44 |
| Alendronate Sodium | Alendronate Sodium | 56 | 17 |
| Bupropion Xl | Bupropion Hcl | 56 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 55 | 49 |
| Januvia | Sitagliptin Phosphate | 54 | 13 |
| Nystatin | Nystatin | 52 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 12 |
| Tramadol Hcl | Tramadol Hcl | 50 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 15 |
| Atenolol | Atenolol | 46 | suppressed |
| Mirtazapine | Mirtazapine | 46 | 17 |
| Trulicity | Dulaglutide | 46 | suppressed |
| Mupirocin | Mupirocin | 45 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 11 |
| Nifedipine Er | Nifedipine | 41 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 41 | 12 |
| Azithromycin | Azithromycin | 40 | 36 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 40 | suppressed |
| Valsartan | Valsartan | 40 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | 20 |
| Donepezil Hcl | Donepezil Hcl | 38 | 13 |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Acyclovir | Acyclovir | 35 | 14 |
| Glyxambi | Empagliflozin/Linagliptin | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Colchicine | Colchicine | 30 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | 11 |
| Megestrol Acetate | Megestrol Acetate | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 17 |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | 11 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 23 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | 11 |
| Fluconazole | Fluconazole | 22 | 21 |
| Glipizide Er | Glipizide | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 22 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 17 |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Humira(Cf) Pen | Adalimumab | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 11 |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $345.70 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Extended Holter, FARXIGA, MOUNJARO, QULIPTA, REXULTI, SHINGRIX, UBRELVY, VRAYLAR, Wegovy | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error